The proportion of gastric residue was statistically significantly higher in the GLP-1 receptor agonist treatment group at 5.4% compared to 0.49% in the non-treatment group (P = 0.004).
GLP-1 receptor agonist () treatment is associated with increased gastric residue as observed during .
The study included a matched pair case-control design with 1,128 individuals with diabetes, ultimately analyzing 205 matched pairs.
Statistical analysis was performed using the McNemar test to compare gastric residue presence between treatment and non-treatment groups.
Gastric residue was observed in 11 patients who received various GLP-1RA medications, including liraglutide, dulaglutide, and semaglutide.
Simplified
AIMS/INTRODUCTION: Previous studies have reported that the glucagon-like peptide-1 receptor agonist () delays gastric emptying, and gastric emptying was assessed by theC breath test or paracetamol absorption technique. However, neither of them is clinically familiar in real-world clinical practice. The purpose of the present study was to investigate the association between GLP-1RA treatment and gastric residue in an . 13
MATERIALS AND METHODS: This study was a matched pair case-control study. The study population consisted of 1,128 individuals with diabetes who had esophagogastroduodenoscopy at our clinic between July 2020 and June 2022. To account for differences in characteristics, such as age, sex, insulin treatment and glycated hemoglobin, we carried out a one-to-one nearest neighbor propensity score matching analysis between diabetes patients with and without GLP-1RA treatment. After matching, we compared the presence of gastric residue in an esophagogastroduodenoscopy by the McNemar test between patients with and without GLP-1RA treatment.
RESULTS: After the propensity score matching, we selected 205 pairs. In the propensity score-matched comparison, the proportion of gastric residue was statistically significantly higher in the GLP-1RA treatment group (0.49% vs 5.4%, P = 0.004). The details of GLP-1RA prescribed for the 11 patients with gastric residue were liraglutide once daily 1.8 mg (n = 2), dulaglutide once weekly 0.75 mg (n = 5), semaglutide once weekly 0.5 mg (n = 2) and semaglutide once weekly 1.0 mg (n = 2).
CONCLUSION: GLP-1RA treatment is associated with gastric residue in an esophagogastroduodenoscopy in patients with diabetes.
Key numbers
5.4%
Increase in Gastric Residue Proportion
Proportion of gastric residue in -treated patients
0.49%
Gastric Residue in Non-treated Patients
Proportion of gastric residue in patients not treated with
205 pairs
Matched Patient Pairs
Number of matched pairs analyzed for gastric residue
Full Text
We can’t show the full text here under this license.
